Telomerase gene therapy supplies cells with instructions for maintaining chromosome ends to preserve tissue renewal. Laboratory and animal findings support investigation, but longevity benefits in health-focused adults remain unproven. Human evidence combines two genes, leaving telomerase’s contribution unresolved. Potential harms include abnormal cell growth and delivery-related organ injury. Persistent gene activity limits reversibility; human benefit, risk, and duration remain undefined. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Blood counts and platelets | No established hTERT target; baseline/laboratory ranges | Detect blood-cell injury |
| Liver enzymes and bilirubin | No established hTERT target; baseline/laboratory upper limits | Detect liver injury |
| Creatinine and estimated kidney filtration | No established hTERT target; baseline/laboratory ranges | Detect kidney injury; pair with urine testing and platelets |
| Blood clotting time | No established hTERT target; baseline/laboratory range | Assess liver function/bleeding |
| Anti-vector neutralizing antibodies | No universal target; product-validated assay/eligibility cutoff | Estimate delivery barriers |
| Telomere length | No validated optimal treatment target; same-method baseline/age-adjusted distribution | Explore target engagement; not a proven longevity surrogate |
| Functional and cognitive measures | No established hTERT target; prespecified meaningful baseline change | Measure useful outcomes; walking/strength and cognitive tests |
| Pregnancy testing | Where relevant | Baseline research assessment |
Cadence: Baseline; weeks 1, 4, 13, 26, 39, 52 in the registered aging protocol. Acute toxicity may require earlier/more frequent tests; persistent expression warrants product-specific multiyear follow-up. No validated hTERT target ranges.